WO2006040462A1 - Composés bi-aromatiques à usage thérapeutique ou cosmétique - Google Patents
Composés bi-aromatiques à usage thérapeutique ou cosmétique Download PDFInfo
- Publication number
- WO2006040462A1 WO2006040462A1 PCT/FR2005/002487 FR2005002487W WO2006040462A1 WO 2006040462 A1 WO2006040462 A1 WO 2006040462A1 FR 2005002487 W FR2005002487 W FR 2005002487W WO 2006040462 A1 WO2006040462 A1 WO 2006040462A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hydroxy
- tetramethyl
- ethoxy
- hydroxyimino
- benzoic acid
- Prior art date
Links
- 0 CC(C)(CCC(C)(C)C1=C2)C1=CC[C@]2C(COc1ccc(C(O*)=O)c(*)c1)=NO Chemical compound CC(C)(CCC(C)(C)C1=C2)C1=CC[C@]2C(COc1ccc(C(O*)=O)c(*)c1)=NO 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
- C07C251/32—Oximes
- C07C251/34—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
- C07C251/48—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with the carbon atom of at least one of the oxyimino groups bound to a carbon atom of a six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
Definitions
- the present invention relates to novel bi-aromatic compounds derived from a salicylic unit, their preparation process and their use in human and veterinary medicine and in cosmetics.
- a family of bi-aromatic compounds derived from a salicylic unit has been described in patent EP 0 514 264. These compounds are described as having an application in the topical and systemic treatment of dermatological disorders related to a disorder of keratinization and disorders. ophthalmological conditions, in particular.
- the invention provides such compounds, which further have the advantage of having a very short hepatic half-life time, advantageously of the order of 3 minutes, and of being perfectly compatible with topical application.
- the subject of the present invention is the compounds of general formula (I)
- R 1 represents: an alkyl radical having from 2 to 20 carbon atoms
- R 2 represents a hydrogen atom or an alkyl having 1 to 3 carbon atoms, and the salts of the compounds of formula (I), when R 1 represents an amino acid residue and the isomers of the compounds of formula (I) .
- Compounds of the invention of formula (I) defined as above having a sufficiently acid function or a sufficiently basic function or both, may include the corresponding salts of organic or inorganic acid or organic or inorganic base pharmaceutically acceptable.
- the invention also relates to tautomeric forms, enantiomers, diastereoisomers, epimers and organic or inorganic salts of the compounds of general formula (I).
- the following terms unless otherwise stated, are to be understood as having the following meanings:
- alkyl radical is meant an aliphatic hydrocarbon group which may be linear or branched having from 2 to 20 carbon atoms in the chain. Preferred alkyl groups have from 2 to 12 carbon atoms in the chain, and especially from 4 to 12 carbon aromas.
- Branched alkyl means that one or more lower alkyl group (s), such as methyl, ethyl or propyl, are attached to a linear alkyl chain.
- Lower alkyl refers to a radical having 1 to 4 carbon atoms in the chain which may be linear or branched.
- alkyl radicals mention may especially be made of ethyl, isopropyl, n-propyl, tert-butyl, n-butyl, n-pentyl, n-hexyl and n-heptyl. and n-octyl.
- alkenyl is meant an aliphatic hydrocarbon group which contains a carbon-carbon double bond and which may be linear or branched, having 2 to 15 atoms of carbon in the chain.
- Preferred alkenyl groups have 2 to 12 carbon atoms in the chain and more preferably 2 to 4 carbon atoms in the chain.
- branched is meant that one or more lower alkyl group (s), such as methyl, ethyl or propyl, are bonded to the linear alkenyl chain.
- alkenyl radicals examples include vinyl, allyl, 2-butenyl, n-butenyl, 3-methylbut-2-enyl, n-pentenyl, hexenyl and heptenyl radicals. octenyl, cyclohexylbutenyl and decenyl.
- monohydroxyalkyl radical an alkyl radical as defined herein, substituted with a hydroxy group.
- monohydroxyalkyl radicals mention may especially be made of the hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl and hydroxyhexyl radicals.
- polyhydroxyalkyl radical is meant an alkyl radical as defined herein, preferably comprising from 2 to 6 carbon atoms, substituted with 2 to 5 hydroxyl groups.
- examples of polyhydroxyalkyl radicals include 2,3-dihydroxypropyl, 2,3,4-trihydroxybutyl and 2,3,4,5-tetrahydroxypentyl radicals.
- the term "residue of a sugar” means a residue derived for example from glucose, galactose or mannose. Examples include 6-glucosyl, 6-galactosyl and 6-mannosyl radicals.
- amino acid refers to a group containing both an amino group and a carboxyl group of the general formula HOOC-CH (side chain) (NH 2 ).
- the amino acids may be in the D, L or racemic configuration.
- Amino acids include both natural and unnatural amino acids.
- Natural amino acids include the 20 constituent amino acids of proteins such as serine, threonine and tyrosine.
- Non-natural amino acids are known and include naturally occurring amino acid analogues.
- Non-naturally occurring amino acids include amino acids in which the side chains are replaced by synthetic derivatives.
- amino acids in which the side chain comprises one or more functions are particularly preferred.
- Examples of naturally occurring amino acids bearing a hydroxyl function are serine, threonine and tyrosine.
- amino acid residue is meant in the sense of the present description the residue of the amino acid after reaction of a hydroxyl group carried by the side chain thereof with a carboxylic acid function to form an ester function of the type :
- pharmaceutically acceptable salts refers to relatively non-toxic, inorganic or organic acid addition salts, and base addition salts, of the compounds of the present invention. These salts can be prepared in situ during the final isolation and purification of the compounds.
- the acid addition salts can be prepared by separately reacting the purified compound in its purified form with an organic or inorganic acid and isolating the salt thus formed.
- acid addition salts are the hydrobromide, hydrochloride, sulfate, bisulfate, phosphate, nitrate, acetate, oxalate, valerate, oleate, palmitate, stearate, laurate, borate, benzoate, lactate, phosphate, tosylate and citrate salts.
- the acid addition salts can also be prepared by separately reacting the purified compound in its form. acid with an organic or inorganic base and isolating the salt thus formed.
- Acidic addition salts include amine and metal salts. Suitable metal salts include sodium, potassium, calcium, barium, zinc, magnesium and aluminum salts. Sodium and potassium salts are preferred.
- Suitable basic inorganic addition salts are prepared from metal bases which include sodium hydride, sodium hydroxide, sodium hydroxide and the like. potassium, calcium hydroxide, aluminum hydroxide, lithium hydroxide, magnesium hydroxide, zinc hydroxide.
- Suitable base amino acid addition salts are prepared from amines which have sufficient alkalinity to form a stable salt, and preferably include amines which are often used in medicinal chemistry because of their low toxicity and acceptability.
- ammonia ethylenediamine, N-methylglucamine, lysine, arginine, ornithine, choline, N, N'-dibenzylethylenediamine, chloroprocaine, diethanolamine, procaine, N-benzylphenethylamine, diethylamine, piperazine, tris (hydroxymethyl) ) -aminomethane, tetramethylammonium hydroxide, triethylamine, dibenzylamine, ephenamine, dehydroabietylamine, N-ethyl-piperidine, benzylamine, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, ethyl
- the compounds of the present invention may contain asymmetric centers.
- These asymmetric centers can be independently in the R or S configuration.
- Some compounds may also exhibit geometric isomerism.
- the present invention includes individual geometric isomers and stereoisomers and mixtures thereof, including racemic mixtures, of compounds of formula (I) above.
- R 1 represents an alkyl radical, and in particular an alkyl radical having 2 to 6 carbon atoms.
- R 2 represents an alkyl group as defined above and having from 1 to 3 carbon atoms such as methyl, ethyl, n-propyl, isopropyl.
- R 2 represents a hydrogen atom.
- R 2 represents a hydrogen atom.
- the compounds of general formula (I) may be prepared by application or adaptation of any method known per se of and / or within the scope of those skilled in the art, especially those described by Larock in Comprehensive Organic Transformations, VCH Pub., 1989, or by application or adaptation of the methods described in the examples which follow, or, more particularly, according to the method described in patent EP 0 514 264.
- it may be necessary to protect the reactive functional groups for example the hydroxy, amino, carboxy groups, when desired in the final product, to avoid their undesirable participation in the reactions.
- Traditional protection groups can be used in accordance with standard practice, for examples see TW Green and PGM Wuts in Protective Groups in Organic Chemistry, John Wiley and Sons, 1991; JFW McOmie in Protective Groups in Organic Chemistry, Plenum Press, 1973.
- the base products or reagents used are commercially available and / or can be prepared by the application or adaptation of known methods, for example processes as described in the examples or their chemical equivalents.
- the compounds of formula (I) may be prepared according to routes A or B as represented in the synthesis scheme of FIG.
- the present invention therefore also relates to a process for the preparation of the compounds of formula (I) described above comprising the following steps: i) conversion of the ketone function of the compound of formula 3
- R 1 represents: an alkyl radical having from 2 to 20 carbon atoms
- alkenyl radical having from 2 to 20 carbon atoms
- a mono- or polyhydroxyalkyl radical having from 1 to 6 carbon atoms
- R 2 represents a hydrogen atom or an alkyl having 1 to 3 carbon atoms, in oxime function to yield the compound of formula (I);
- the conversion of the ketone function to oxime can be carried out according to known methods.
- the oxime may be prepared by reacting hydroxylamine or a salt thereof, such as a hydroxylamine hydrohalide and in particular hydroxylamine hydrochloride, with ketone.
- Hydroxylamine derivatives such as, for example, H 2 NOSO 3 H and HON (SO 3 Na) 2 can also be used.
- the ratio of the hydroxylamine, its salts or its derivatives to the ketone compound 3 can vary, for example, in the range from 1 to 20 molar equivalents, more preferably from 1 to 5 molar equivalents.
- the amount of hydroxylamine hydrochloride and pyridine is, for example, respectively 1 mol to 1 mol of compound 3.
- the oxime may also be prepared by reacting compound 3 with a combination of hydroxylamine halohydrate and pyridine.
- these two reagents are present in proportions (1/1) in molar equivalents respectively.
- Step (i) can also be performed in the presence of a suitable base.
- a suitable base There is no particular restriction on the nature of the basis in this reaction, and any basis traditionally used in reactions of this type can be used here provided that it has no adverse effect on other parts of the molecule.
- Suitable bases include alkali metal hydroxides such as potassium hydroxide and sodium hydroxide, amines such as triethylamine, diisopropylethylamine, and the like.
- suitable solvents include polar solvents, including aliphatic alcohols such as methanol, ethanol, isopropanol; aliphatic ethers such as tetrahydrofuran (THF), diethyl ether, dibutyl ether, dioxane; and mixtures of these solvents.
- polar solvents including aliphatic alcohols such as methanol, ethanol, isopropanol; aliphatic ethers such as tetrahydrofuran (THF), diethyl ether, dibutyl ether, dioxane; and mixtures of these solvents.
- the reaction can take place over a wide temperature range, and it is not essential for the invention that the reaction be performed at a precise temperature.
- the reaction temperature is, for example, between 15 ° C and 150 ° C and, most often, between 20 0 C and 100 0 C.
- reaction may be carried out under reflux of methanol and / or THF.
- the compound of formula 3 is prepared according to a process comprising an esterification reaction of acid 1, according to a step a 1), in the presence of an alcohol R 1 Wherein R 1 is as defined above, whereby a compound of formula 2 is obtained.
- the esterification reaction according to step a1) can be catalyzed by a suitable acid.
- suitable acid examples include hydrochloric, hydrobromic, nitric or sulfuric acid, the latter being preferred.
- the process for preparing the compound of formula 3 additionally comprises an alkylation reaction of the phenol function of compound 2 in the presence of an alkyl halide of formula R 2 X, in which R 2 represents an alkyl having 1 to 3 carbon atoms, and X represents a halogen atom such as Cl or Br.
- This alkylation reaction can be carried out according to conventional methods.
- reference may be particularly March, Jerry, Advanced Organic Chemistry, 3rd Ed., John Wiley and Sons.
- the alkylation reaction can be carried out in the presence of a suitable base.
- suitable bases include alkali metal carbonates such as potassium carbonate, sodium carbonate or cesium carbonate; alkali metal hydroxides, such as sodium hydroxide or potassium hydroxide.
- Step b2) the compound 3 is prepared by an alkylation reaction of a haloacetophenone 6, in particular bromoacetophenone, with a compound of formula 5.
- This alkylation reaction can be carried out according to known methods.
- reference may be particularly March, Jerry, Advanced Organic Chemistry, 3rd Ed., John Wiley and Sons.
- the alkylation reaction can be carried out in the presence of a suitable base.
- suitable bases are in particular alkali metal carbonates such as potassium carbonate, sodium carbonate or cesium carbonate, alkali metal hydroxides, such as sodium hydroxide or potassium hydroxide or potassium hydroxide. potassium carbonate, the latter being particularly preferred.
- the compound 5 can be prepared by an esterification reaction of dihydrobenzoic acid with an alcohol R 1 OH, followed by an alkylation reaction with an alkyl halide R 2 X, according to conventional methods.
- the compounds of formula (I) are prepared according to the following steps: 1) esterification of 2-hydroxy-4- [2-hydroxyimino-2 acid - (5,5,8,8-tetra ⁇ methyl-
- the compound (I) thus prepared and, if appropriate, the intermediates 2 and 5 can be recovered from the reaction mixture by conventional means.
- the compounds can be recovered by distilling the solvent from the reaction mixture or if necessary after distilling the solvent from the solution mixture, pouring the remainder into water followed by extraction with an organic solvent immiscible in the reaction mixture. water, and distilling the solvent from the extract.
- the product may, if desired, be further purified by various techniques, such as recrystallization, reprecipitation or various chromatography techniques, including column chromatography or preparative thin layer chromatography.
- the subject of the present invention is also the compounds of formula (I) as described above as a medicament.
- the invention relates to a pharmaceutical or cosmetic composition characterized in that it comprises in a pharmaceutically or cosmetically acceptable vehicle at least one compound of formula (I) above.
- pharmaceutically or cosmetically acceptable vehicle is meant a suitable vehicle for use in contact with cells of humans and animals, without toxicity, irritation, undue allergic response and the like, and proportionate to a reasonable risk / benefit ratio .
- Administration may be topical, enteral or oral, parenteral or ocular.
- the topical route is particularly preferred.
- the pharmaceutical composition according to the invention is more particularly intended for the treatment of the skin and mucous membranes and may be in liquid, pasty or solid form, and more particularly in the form of ointments, creams, milks , ointments, powders, soaked swabs, syndets, solutions, gels, sprays, mousses, suspensions, sticks, shampoos, or washing bases. It may also be in the form of suspensions of microspheres or nanospheres or lipid or polymeric vesicles or polymeric or gelled patches allowing controlled release.
- the compounds are used topically at a concentration generally of between 0.001% and 3% by weight, relative to the total weight of the composition.
- the composition is preferably in the form of a cream, a milk, a lotion, a gel, microspheres or nanospheres or lipid or polymeric vesicles, a soap, a shampoo.
- the composition may be in the form of tablets, capsules, dragees, syrups, suspensions, solutions, powders, granules, emulsions, suspensions of microspheres or nanospheres, or lipid or polymeric vesicles for controlled release.
- the composition may be in the form of solutions or suspensions for infusion or injection.
- the compounds according to the invention are generally administered at a daily dose of about 0.01 mg / kg to 30 mg / kg of body weight, in 1 to 3 doses.
- the compounds according to the invention can advantageously act as prodrugs.
- prodrugs means that the compounds are transformed in vivo to give the parent compound, 2-hydroxy-4- [2-hydroxyimino-2- (5,5,8,8-tetramethyl-5,6,7, 8-tetrahydro-naphthalen-2-yl) -ethoxy] -benzoic, by hydrolysis in the human or animal body.
- the compounds of the invention are useful, alone or in admixture, for the preparation of a pharmaceutical or cosmetic composition wherein said compound is an agent exerting selective RAR gamma receptor agonist activity.
- the invention also relates to a method of therapeutic or cosmetic treatment, comprising the administration of a pharmaceutical or cosmetic composition comprising such a compound, as an agent exerting a selective agonist activity of the RAR gamma receptor.
- the pharmaceutical composition may be more particularly intended to treat a pathology for the treatment of which a selective agonist activity of the RAR gamma receptor is desired.
- composition is also useful for the treatment of a pathology related to the disorders of cell differentiation or proliferation, particularly in the field of dermatology.
- acne is thus envisaged, in particular vulgar, comedonal, polymorphic acne, nodulocystic acne, conglobata, senile acnes, secondary acne such as solar acne, medicated, professional acne.
- the pharmaceutical composition comprising a compound of the invention is also useful for treating other dermatological conditions related to a disorder of keratinization with an inflammatory and / or immunoallergic component and, in particular, all forms of psoriasis, whether cutaneous , mucous or ungueal.
- the compounds of the invention are also useful in a cosmetic composition for combating cutaneous aging, whether it is for example photoinduced or chronological.
- the pharmaceutical or cosmetic composition also makes it possible to reduce skin pigmentations and to treat actinic keratoses.
- the compound of the invention may be combined with another therapeutic agent useful in the treatment of a pathology related to the disorders of cell differentiation or proliferation.
- reaction medium is treated with a 1N hydrochloric acid solution, extracted with ethyl acetate.
- the residue obtained after drying and concentration is purified by chromatography on a silica column (eluent heptane 95 / EtOAc 5).
- Activation of the receptors by an agonist (activator) in HeLa cells leads to the expression of a reporter gene, luciferase, which in the presence of a substrate generates light.
- Receptor activation can therefore be measured by quantifying the luminescence produced after incubation of the cells in the presence of a reference antagonist.
- the activating products move the antagonist of its site thus allowing the activation of the receptor.
- the measurement of the activity is done by the quantification of the increase of the light produced. This measurement makes it possible to determine the activating activity of the compound useful in the invention.
- a constant is determined which represents the affinity of the molecule for the receptor. Since this value can fluctuate according to the basal activity and the expression of the receptor, it is called apparent Kd (KdApp).
- 2-yl) -ethoxy] -benzoic acid against a reference antagonist otherwise named reference ligand, 4- (5,5-Dimethyl-8-p-tolyl-5,6-dihydro-naphthalen-2- ylethynyl) -benzoic acid are produced.
- the test product is used at 10 concentrations and the reference antagonist at 7 concentrations.
- the cells are in contact with a concentration of the test product and a concentration of the reference antagonist.
- I ⁇ C50 concentration giving 50% of the activity
- the HeLa cell lines used are stable transfectants containing the ERE- ⁇ Glob-Luc-SV-Neo plasmids (reporter gene) and RAR ( ⁇ , ⁇ , Y) ER-DBD-puro. These cells are inoculated into 96-well plates at the rate of 10,000 cells per well in
- the culture medium is removed by inversion and 100 ⁇ l of a mixture of 1: 1 PBS (phosphate buffer solution) / Luciferine is added to each well. After 5 minutes, the plates are read by the luminescence reader.
- 1 PBS phosphate buffer solution
- Luciferine phosphate buffer solution
- 2-Hydroxy-4- [2-hydroxyimino-2- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -ethoxy] benzoic acid is a agonist or selective activator of the RARgamma receptor.
- mice The irritancy of ethyl ester and isobutyl ester of 2-hydroxy-4- [2-hydroxyimino-2- (5,5,8,8-tetramethyl) -5,6,7,8- Tetrahydronaphthalen-2-yl) -ethoxy] -benzoic acid (compounds of Examples 1 and 3 respectively) is evaluated by single topical application to the ear in BALB / c mice.
- the mice (ByJlco) are female mice aged 8 weeks. A batch of 5 mice is tested.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Cosmetics (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007536212A JP2008515958A (ja) | 2004-10-12 | 2005-10-10 | 治療用途または化粧品用途のための二芳香族化合物 |
CA002582248A CA2582248A1 (fr) | 2004-10-12 | 2005-10-10 | Composes bi-aromatiques a usage therapeutique ou cosmetique |
EP05809265A EP1802569A1 (fr) | 2004-10-12 | 2005-10-10 | Composés bi-aromatiques à usage thérapeutique ou cosmétique |
US11/783,662 US20070249710A1 (en) | 2004-10-12 | 2007-04-11 | Biaromatic compounds and cosmetic/pharmaceutical applications thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0410749 | 2004-10-12 | ||
FR0410749A FR2876376B1 (fr) | 2004-10-12 | 2004-10-12 | Composes bi-aromatiques a usage therapeutique ou cosmetique |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006040462A1 true WO2006040462A1 (fr) | 2006-04-20 |
Family
ID=34952479
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2005/002487 WO2006040462A1 (fr) | 2004-10-12 | 2005-10-10 | Composés bi-aromatiques à usage thérapeutique ou cosmétique |
Country Status (6)
Country | Link |
---|---|
US (1) | US20070249710A1 (fr) |
EP (1) | EP1802569A1 (fr) |
JP (1) | JP2008515958A (fr) |
CA (1) | CA2582248A1 (fr) |
FR (1) | FR2876376B1 (fr) |
WO (1) | WO2006040462A1 (fr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2010232556A1 (en) * | 2009-04-02 | 2011-11-03 | Allergan, Inc. | Prostaglandin E receptor antagonists |
CA2805808A1 (fr) * | 2010-07-23 | 2012-01-26 | Connexios Life Sciences Pvt. Ltd. | Agonistes de gpr40 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0514264A1 (fr) * | 1991-05-13 | 1992-11-19 | Centre International De Recherches Dermatologiques Galderma, ( Cird Galderma) | Composés bi-aromatiques dérivés d'un motif salicylique, leur procédé de préparation et leur utilisation en médecine humaine et vétérinaire ainsi qu'en cosmétique |
-
2004
- 2004-10-12 FR FR0410749A patent/FR2876376B1/fr not_active Expired - Fee Related
-
2005
- 2005-10-10 CA CA002582248A patent/CA2582248A1/fr not_active Abandoned
- 2005-10-10 EP EP05809265A patent/EP1802569A1/fr not_active Withdrawn
- 2005-10-10 JP JP2007536212A patent/JP2008515958A/ja active Pending
- 2005-10-10 WO PCT/FR2005/002487 patent/WO2006040462A1/fr active Application Filing
-
2007
- 2007-04-11 US US11/783,662 patent/US20070249710A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0514264A1 (fr) * | 1991-05-13 | 1992-11-19 | Centre International De Recherches Dermatologiques Galderma, ( Cird Galderma) | Composés bi-aromatiques dérivés d'un motif salicylique, leur procédé de préparation et leur utilisation en médecine humaine et vétérinaire ainsi qu'en cosmétique |
Also Published As
Publication number | Publication date |
---|---|
FR2876376B1 (fr) | 2007-01-19 |
JP2008515958A (ja) | 2008-05-15 |
FR2876376A1 (fr) | 2006-04-14 |
EP1802569A1 (fr) | 2007-07-04 |
US20070249710A1 (en) | 2007-10-25 |
CA2582248A1 (fr) | 2006-04-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1963250B1 (fr) | Derives biphenyliques agonistes selectifs du recepteur rar-gamma | |
EP1044966B1 (fr) | Composés (poly)thia-alcynoiques et leurs dérivés, compositions les comprenant et leur utilisation | |
FR2935380A1 (fr) | Nouveaux composes hexafluoro-2-biphenyl-isopropanol, modulateurs des recepteurs de type lxrs, leur procede de preparation et leur application comme medicaments en medecine humaine ou veterinaire ainsi qu'en cosmetique. | |
EP1963249B1 (fr) | Derives biphenyliques agonistes selectifs du recepteur rar-gamma | |
EP0021940B1 (fr) | Nouveaux dérivés aminés du benzothiazole, leur procédé de préparation et leur application en thérapeutique | |
FR2584400A1 (fr) | Esters et amides de l'acide eicosatriynoique et leur application en pharmacie et en cosmetique | |
EP2164827A2 (fr) | Nouveaux dérivés d'acide 3-phenyl acrylique activateurs des récepteurs de type ppar, leur méthode de préparation et leur utilisation dans des compositions cosmétiques ou pharmaceutiques | |
EP1802569A1 (fr) | Composés bi-aromatiques à usage thérapeutique ou cosmétique | |
EP2146951B1 (fr) | Nouveaux ligands agonistes des recepteurs rars, utilisation en medecine humaine ainsi qu'en cosmetique | |
EP1680395B1 (fr) | NOUVEAUX LIGANDS ACTIVATEURS DES RECEPTEURS RARs, UTILISATION EN MEDECINE HUMAINE AINSI QU'EN COSMETIQUE | |
EP2155662B1 (fr) | Nouveaux derives d'acide 3-phenyl propanoique activateurs des recepteurs de type ppar, leur methode de preparation et leur utilisation dans des compositions cosmetiques ou pharmaceutiques | |
FR2874379A1 (fr) | Nouveaux composes bi-aromatiques activateurs des recepteurs de type ppar et leur utilisation dans des compositions cosmetiques ou pharmaceutiques | |
CH682322A5 (fr) | ||
EP0733627A1 (fr) | Nouveaux composés du thiophene, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent | |
WO2006090072A1 (fr) | Derives activateurs de ppar, procede de preparation et application en therapeutique | |
FR3097749A1 (fr) | Utilisation d’un compose flavone pour limiter la quantité de sébum sur la peau, composés flavones et composition les contenant | |
LU85562A1 (fr) | Nouveaux derives 1-substitutes du methoxy-4 trimethyl-2, 3, 6 benzene,leur procede de preparation et compositions medicamenteuse et cosmetique les contenant | |
FR2861393A1 (fr) | Nouveau ligand activateur des recepteurs rarbeta, son procede de preparation et son utilisation en medecine humaine ainsi qu'en cosmetique. | |
FR2741803A1 (fr) | Application de 2-aminobenzothiazoles dans le traitement de la maladie de parkinson et des syndromes parkinsoniens | |
FR2888846A1 (fr) | Nouveaux derives de cyclopent-2-en-1-one, modulateurs des recepteurs ppars et leur utilisation dans des compositions pharmaceutiques ou cosmetiques |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005809265 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2582248 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007536212 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWP | Wipo information: published in national office |
Ref document number: 2005809265 Country of ref document: EP |